Is there a connection between EDS and MCAS?

‍

The Link Between Ehlers-Danlos Syndrome and Mast Cell Activation Syndrome

Ehlers-Danlos Syndrome (EDS) and Mast Cell Activation Syndrome (MCAS) have emerged as interconnected conditions, particularly in patients with hypermobile Ehlers-Danlos Syndrome (hEDS). While these two conditions are distinct, their overlap has significant implications for diagnosis, treatment, and patient outcomes. Both EDS and MCAS involve dysregulation of connective tissues and immune system responses, often resulting in a complex array of symptoms that affect multiple body systems. Understanding how these conditions interact can help healthcare providers better diagnose and treat patients who suffer from both.

Ehlers-Danlos Syndrome: A Foundation of Connective Tissue Instability

EDS is a group of inherited connective tissue disorders that affects the structure and function of collagen, the primary building block of skin, joints, and blood vessels. There are 13 recognized subtypes of EDS, with hypermobile EDS (hEDS) being the most common. hEDS is primarily characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. Although genetic markers have been identified for many forms of EDS, hEDS remains an exception, with no known gene to definitively diagnose it.

One of the challenges for individuals with hEDS is that the symptoms often go beyond musculoskeletal issues. In addition to frequent joint dislocations and chronic pain, many hEDS patients experience gastrointestinal problems, cardiovascular dysregulation (such as postural orthostatic tachycardia syndrome, or POTS), and even neurological symptoms like migraines. This complexity makes managing hEDS particularly challenging, as symptoms can vary widely between patients and involve multiple systems.

Mast Cell Activation Syndrome: An Immune System on Overdrive

Mast cells are a crucial part of the immune system, responsible for releasing chemicals like histamine, tryptase, and cytokines during allergic and immune responses. However, in individuals with MCAS, mast cells become overly reactive and release these chemicals inappropriately, even in the absence of allergens or infections. This results in chronic, widespread symptoms that affect multiple organs, including the skin, gastrointestinal tract, cardiovascular system, and nervous system.

MCAS falls under the broader category of mast cell activation disorders (MCAD), which also includes systemic mastocytosis (SM). Unlike systemic mastocytosis, which involves the overproduction of mast cells, MCAS is characterized by non-clonal mast cell hyperactivation, meaning the cells function abnormally without proliferating excessively. The symptoms of MCAS can include flushing, hives, anaphylaxis-like reactions, abdominal pain, diarrhea, migraines, and fatigue.

The Overlap Between EDS and MCAS

There is increasing evidence that individuals with hEDS are more likely to develop MCAS. One reason for this is that mast cells are abundant in connective tissue, which is weakened in EDS patients. This structural abnormality in the connective tissue may cause mast cells to become dysregulated, leading to the chronic release of mediators and triggering symptoms of MCAS. In fact, some studies suggest that up to 25% of hEDS patients may also have MCAS.

The overlap between EDS and MCAS is most evident in shared symptoms affecting the gastrointestinal, cardiovascular, and nervous systems. For example, both conditions can cause gastrointestinal motility issues, leading to symptoms like nausea, diarrhea, and constipation. Cardiovascular symptoms are also common, as many hEDS patients develop postural orthostatic tachycardia syndrome (POTS), which is frequently associated with MCAS. This combination of symptoms can make it difficult for healthcare providers to distinguish between the two conditions without comprehensive testing.

Mechanisms Linking EDS and MCAS

Several biological mechanisms may explain the link between EDS and MCAS. One theory involves the abnormal collagen production in EDS. Collagen is crucial for the structural integrity of connective tissues, and its dysfunction could trigger an immune response. In patients with EDS, the irregular collagen might act as a persistent irritant to mast cells, causing chronic activation. This could explain why patients with hEDS are more likely to develop MCAS.

Additionally, genetic factors may play a role. Recent studies have identified a genetic variant known as hereditary alpha-tryptasemia, which is associated with elevated basal serum tryptase levels. This condition is linked to both mast cell activation and connective tissue disorders like EDS. Individuals with this variant are at higher risk for developing MCAS symptoms, including those related to gastrointestinal distress and cardiovascular instability.

Shared Symptoms and Diagnostic Challenges

The overlap in symptoms between EDS and MCAS can make diagnosis particularly challenging. Some of the most common shared symptoms include:

• Gastrointestinal issues: Both EDS and MCAS patients frequently report problems such as nausea, bloating, constipation, and diarrhea. These symptoms can be caused by dysregulated mast cells in the digestive tract or by abnormal connective tissue in the gastrointestinal system.
• Cardiovascular symptoms: Many hEDS patients develop POTS, a condition characterized by a rapid heart rate upon standing, which can be exacerbated by the mast cell dysregulation seen in MCAS. Patients often experience dizziness, lightheadedness, and fainting, further complicating diagnosis.
• Neurological symptoms: Migraines, fatigue, and brain fog are common in both conditions. In MCAS, these symptoms may be linked to the overactivation of mast cells in the brain, while in EDS, they could result from autonomic dysfunction.

Gastrointestinal and Autonomic Dysregulation

Gastrointestinal issues are a hallmark of both EDS and MCAS, with many patients experiencing chronic nausea, diarrhea, and abdominal pain. The gastrointestinal tract is rich in mast cells, which play an essential role in regulating gut motility and inflammation. In MCAS, these cells become overly reactive, leading to gastrointestinal distress. Similarly, in hEDS, the connective tissue abnormalities may cause structural issues within the gut, such as hernias or motility problems, further exacerbating symptoms.

Autonomic dysfunction, such as POTS, is another area where the overlap between EDS and MCAS becomes evident. POTS affects the body’s ability to regulate blood pressure and heart rate, causing symptoms like dizziness and fainting. Many patients with POTS also exhibit symptoms of MCAS, including flushing, gastrointestinal issues, and fatigue. This overlap suggests that the dysregulation of both the autonomic nervous system and mast cells may be driving these symptoms.

Diagnosis and Treatment

Diagnosing MCAS in patients with hEDS can be difficult, as there is no single test that definitively confirms MCAS. Instead, diagnosis often relies on a combination of symptom assessment and laboratory testing for mast cell mediators, such as tryptase, histamine, and prostaglandins. It is essential for clinicians to consider both conditions when evaluating patients with overlapping symptoms and to use a multidisciplinary approach for management.

The treatment of EDS and MCAS together requires a comprehensive strategy. For MCAS, treatment typically involves medications that stabilize mast cells or block the effects of the chemicals they release. These may include antihistamines (H1 and H2 blockers), mast cell stabilizers like cromolyn sodium, and leukotriene receptor antagonists. Patients are also advised to avoid known triggers, such as certain foods, environmental allergens, and stress, which can exacerbate mast cell activation.

For hEDS, physical therapy is often recommended to strengthen muscles and stabilize joints, reducing the risk of dislocations and chronic pain. Managing cardiovascular symptoms, such as those caused by POTS, often involves increasing fluid and salt intake, using compression garments, and sometimes medications to help regulate blood pressure.

Conclusion

The relationship between Ehlers-Danlos Syndrome and Mast Cell Activation Syndrome is an area of growing interest in the medical community. As research continues to uncover the biological mechanisms linking these conditions, healthcare providers will be better equipped to diagnose and manage the complex array of symptoms experienced by patients with both hEDS and MCAS. By understanding the overlap between these disorders, patients can receive more targeted treatments and improve their overall quality of life.

References:

1. Seneviratne, Suranjith L., Anne Maitland, and Lawrence Afrin. "Mast cell disorders in Ehlers-Danlos syndrome." American Journal of Medical Genetics Part C: Seminars in Medical Genetics 175.1 (2017): 226-236. doi:10.1002/ajmg.c.31555.
2. "Mast Cell Activation is Linked to a Wide Range of Other Conditions." EDS Clinic, https://www.eds.clinic/articles/mast-cell-activation-is-linked-to-a-wide-range-of-other-conditions.
3. "The EDS Trifecta." EDS Clinic, https://www.eds.clinic/articles/eds-pots-mcas-trifecta.
4. Cheung, Ingrid, and Peter Vadas. "A new disease cluster: Mast cell activation syndrome, postural orthostatic tachycardia syndrome, and Ehlers-Danlos syndrome." Journal of Allergy and Clinical Immunology 135.2 (2015): AB65. https://doi.org/10.1016/j.jaci.2014.12.1146.
5. Lyons, Jonathan J., et al. "Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number." Nature Genetics, vol. 48, no. 12, 2016, pp. 1564-1569. https://www.nature.com/articles/ng.3696
6. Wong, Sammi, et al. "The gastrointestinal effects amongst Ehlers-Danlos syndrome, mast cell activation syndrome and postural orthostatic tachycardia syndrome." AIMS Allergy and Immunology, vol. 6, no. 2, 2022, pp. 19-24. doi:10.3934/Allergy.2022004.
7. Vadas, Peter, et al. "Cosegregation of postural orthostatic tachycardia syndrome, hypermobile Ehlers-Danlos syndrome, and mast cell activation syndrome." Annals of Allergy, Asthma & Immunology 125.6 (2020): 719-720. doi:10.1016/j.anai.2020.08.015.
8. Krüger-Krasagakes, Sabine, et al. "Adhesion of human mast cells to extracellular matrix provides a co-stimulatory signal for cytokine production." Immunology 98.2 (1999): 253-257. doi:10.1046/j.1365-2567.1999.00865.x.
9. Monaco, Ashley, et al. "Association of mast-cell-related conditions with hypermobile syndromes: A review of the literature." Immunologic Research 70.4 (2022): 419-431. doi:10.1007/s12026-022-09280-1.
10. Royer, Shaina P., and Sangyoon J. Han. "Mechanobiology in the comorbidities of Ehlers-Danlos syndrome." Frontiers in Cell and Developmental Biology 10 (2022): 874840. doi:10.3389/fcell.2022.874840.
11. Dempsey, Tania. "Ehlers-Danlos Syndrome, Hypermobility, and Mast Cell Activation Syndrome: The Connection." Dr. Tania Dempsey. https://drtaniadempsey.com/ehlers-danlos-syndrome-hypermobility-and-mast-cell-activation-syndrome-the-connection.
12. Campbell, Samantha. "Mast Cell Activation in Ehlers-Danlos Syndrome." Mayo Clinic, 2022. https://connect.mayoclinic.org/blog/ehlers-danlos-syndrome/newsfeed-post/mast-cell-activation-in-ehlers-danlos-syndrome.

‍